Macular Degeneration: Medical Treatments

(asked on 29th June 2022) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the (a) development of novel treatments for geographic atrophy and (b) early adoption of new treatments proven to delay the progression of that disease.


Answered by
Maria Caulfield Portrait
Maria Caulfield
Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
This question was answered on 7th July 2022

The Medicines and Healthcare products Regulatory Agency is currently supporting clinical trials for a number of medicines relating to geographic atrophy and will review the quality, safety and efficacy of these products should the manufacturers apply for licences.

The early adoption of new treatments, including for patients with geographic atrophy, is being supported by the Innovative Licensing and Access Pathway, which is enabling the rapid review and approval of promising new medicines. The recently launched Innovative Medicines Fund will also allow patients to benefit from early access to such treatments.

Reticulating Splines